TASK V17: DEVELOPMENT OF ASSAYS AND REAGENTS FOR MONKEYPOX VACCINES

任务 V17：猴痘疫苗测定方法和试剂的开发

• 批准号: 10703295
• 负责人: THOMAS RUDGE
• 金额: $ 104.51万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10703295
• 关键词: Biological; Biological Products; Bioterrorism; Communicable Diseases; Contracts; Development; Emerging Communicable Diseases; Feasibility Studies; Investigational New Drug Application; Licensing; Monkeypox; Poxviridae; Reagent; Services; Vaccines; assay development; evaluation/testing; novel vaccines; product development; testing services; vaccine candidate; vaccine development

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.

传染病疫苗和其他生物制品的评估和测试服务（ETS）合同提供了从早期可行性研究到提交生物许可申请（BLA）和/或研究性新药（IND）申请所需的活动的各种产品开发服务。这些服务将促进开发和引进新的候选疫苗和生物制剂（由生物和生物研究中心管制），以对付潜在的生物恐怖主义制剂以及新出现和重新出现的传染病。